Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
Rhea-AI Summary
Vaxart (OTCQX: VXRT) announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 4:00 PM ET.
The virtual presentation will be webcast and available on the company investor relations website for 30 days following the event; management will also hold one-on-one meetings.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the Feb 18 session, VXRT declined 1.65%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Clinical data update | Positive | +18.4% | Phase 1 data for oral bivalent norovirus vaccine in lactating women and infants. |
| Jan 08 | Conference participation | Positive | +41.7% | Announcement of presentation at Global BioInnovation Forum with senior leadership speakers. |
| Nov 13 | Earnings and update | Positive | +11.0% | Q3 2025 results, Dynavax collaboration, large Phase 2b COVID-19 trial enrollment and cash runway detail. |
| Nov 07 | Investor webcasts | Positive | +7.2% | Planned Q3 earnings call and shareholder fireside chat to discuss results and take questions. |
| Oct 20 | Scientific conference | Positive | -1.4% | IDWeek 2025 presentation on next-generation oral bivalent norovirus vaccine Phase 1 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Vaxart news, including trial data, earnings and conference participation, has often been followed by positive one-day price reactions, with occasional divergences on scientific updates.
Over the last few months, Vaxart has reported multiple catalysts. On Oct 20, 2025, it highlighted Phase 1 data for a second‑generation norovirus oral pill at IDWeek 2025. In November 2025, it hosted investor calls and delivered Q3 2025 earnings with $72.4M revenue and COVID-19 trial progress. January 2026 brought positive norovirus data in lactating women and participation in the Global BioInnovation Forum. Today’s Oppenheimer conference appearance continues this pattern of active investor and scientific engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026.
Presentation Details:
Date and Time: Wednesday, February 25 at 4:00pm ET
Registration and Webcast: Click Here
The webcast will be available on the Company’s investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event.
The Company will participate in one-on-one meetings during the conference. Investors interested in meeting with management may reach out to their Oppenheimer representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
(646) 871-8481
